A simple solution
MoyoMedical Technologies aims to provide urine-based point-of-care early diagnostic test strip. Expecting mothers can use PET Strips at home to periodically self-screen for preeclampsia so they know when to seek medical care before the complication becomes severe.
PET Strip Purpose:
Expecting mothers can use at home to periodically self-screen for preeclampsia so they know when to seek medical care before the complication becomes severe.
To address this ongoing need, our team is developing a urine-based point-of-care early diagnostic test that can be used by women at home during pregnancy to self-screen for preeclampsia so they know when to seek medical care. By seeking medical care at the early onset of preeclampsia, the condition can be appropriately monitored and controlled, thereby reducing the detrimental health impacts of undiagnosed preeclampsia and eclampsia.
Early indicators for developing preeclampsia include dramatically increased levels of the biomarkers activin A and inhibin A in a woman’s urine. The self-diagnostic tool will be a urine strip created by adapting lateral flow immunoassay technology to detect dangerous levels of these biomarkers in the urine of pregnant women. The test will inform the woman if she is developing preeclampsia and needs to seek medical care before her symptoms become severe and endanger the life of her and her unborn child.
This diagnostic test aims to provide a safe, inexpensive, and reliable way for women to know when they are developing preeclampsia and need to seek medical care. With limited access to prenatal care, self-screening with this test can act as an early warning so women can know when to seek care before the symptoms of preeclampsia become severe. The secondary goal of this diagnostic tool is to provide a more specific screening method to assist healthcare providers in a clinical setting make the diagnosis of preeclampsia. When combined with the standard indicator of elevated blood pressure, the early detection of the increase in the biomarker levels of activin A and inhibin A can make the diagnosis more specific.
Making a difference.
The urine-based diagnostic test relies on the early detection of biomarkers like CRD, but is safer, cheaper to manufacture, and would more easily fit into the daily routine of a pregnant woman because our test is relies on urine rather than blood. These improvements increase the likelihood of technology adoption and regular home-based preeclampsia screenings.